Interaction between ionizing radiation and estrogen: What we are missing?

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 966-969

  Fucic, Aleksandra ^a   Gamulin, Marija ^b  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AROMATASE INHIBITOR; CYTOCHROME P450 1B1; ESTROGEN; ESTROGEN RECEPTOR; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P53; TESTOSTERONE; THYROID HORMONE; URANIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULTHOOD; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BONE STRUCTURE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; DNA METHYLATION; DOSIMETRY; GENE LOCUS; GENOME; HEALTH HAZARD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG CANCER; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OCCUPATIONAL HEALTH; PHOSPHORYLATION; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION INJURY; RADIOSENSITIVITY; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION; SPERMATOGENESIS; TESTOSTERONE BLOOD LEVEL; THYROID CANCER; TUMOR GROWTH;

DNA METHYLATION; ESTROGENS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, RADIATION-INDUCED; RADIATION, IONIZING; RECEPTORS, ESTROGEN; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 80755175838     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.08.021     Document Type: Article

References (88)

1. Fucic A., Gamulin M., Ferencic Z., et al. Lung cancer and environmental chemical exposure: a review of our current state of knowledge with reference to the role of hormones and hormone receptors as an increased risk factor for developing lung cancer in man. Toxicol Pathol 2010, 38(6):849-856.
2. Okoh V., Deoraj A., Roy D. Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta 2011, 1815(1):115-133.
3. Tanaka Y., Sasaki M., Kaneuchi M., et al. Estrogen receptor alpha polymorhism and renal cell carcinoma-possible risk. Mol Cell Endocrinol 2003, 202:109-116.
4. Lowenfels A.B., Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenteol 2006, 20(2):197-209.
5. Mendez P., Wandosell F., Garcia-Segura L.M. Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: cellular and molecular mechanisms. Front Neuroendocrinol 2006, 27(4):391-403.
6. Eick G.N., Thornton J.W. Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. Mol Cell Endocrinol 2011, 334(1-2):31-38.
7. Jefferson W.N., Williams C.J. Circulating levels of genistein in the neonate apart from doseroute predict future adverse female reproductive outcomes. Rep Toxicol 2011, 31(3):272-279.
8. Levin E.R. Cellular functions of plasma membrane estrogen receptors. Steroids 2002, 67:471-475.
9. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005, 19:1951-1959.
10. Simoncini T., Mannella P., Fornari L., Caruso A., Varone G., Genazzani A.R. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004, 69(8-9):537-542.
11. Sergeev P.V., Ukhina T.V., Gurevich K.G., Shimanovskii N.L. On the mechanisms of various dose - effect relationships for estrogens. Pharm Chem J 2001, 35:468-470.
12. González M., Cabrera-Socorro A., Pérez-García C.G., et al. Distribution patterns of estrogen receptor alpha and beta in the human cortex and hippocampus during development and adulthood. J Comp Neurol 2007, 503(6):790-802.
13. Lemmen J.G., Arends R.J., van Boxtel A.L., et al. Tissue and time dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 2004, 32:689-701.
14. Kang L., Zhang X., Xie Y., et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010, 24(4):709-721.
15. Balhuizen A., Kumar R., Amisten S., et al. Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrinol 2010, 320(1-2):16-24.
16. Chen G.C., Zeng Q., Tse G.M.K. Estrogen and its receptors in cancer. Med Res Rev 2008, 28(6):954-974.
17. Toillon R.A., Magne N., Lai{dotless}os I., et al. Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells. Breast Cancer Res Treat 2005, 93:207-215.
18. Ma H., Hill C.K., Bernstein L., et al. Low-dose medical radiation exposure and breast cancer risk in women under age 50 years overall and by estrogen and progesterone receptor status: results from a case-control and case-case comparison. Brest Cancer Res Treat 2008, 109(19):77-90.
19. Noshchenko A.G., Moysich K.B., Bondar A., et al. Patterns of acute leukaemia occurrence among children in the Chernobyl region. Int J Epidemiol 2000, 30(1):125-129.
20. Albrecht E.D., Lane M.V., Marshall G.R., et al. Estrogen promotes germ cell and seminiferous tubule development in the baboon fetal testis. Biol Reprod 2009, 81(2):406-414.
21. Carreau S., Wolczynski S., Galeraud-Denis I. Aromatase, oestrogens and human male reproduction. Philos Trans R Soc Lond B Biol Sci 2010, 365(1546):1571-1579.
22. Lazaros L.A., Xita N.V., Kaponis A.I. Estrogen receptor alpha and beta polymorphisms are associated with semen quality. J Androl 2010, 31(3):291-298.
23. Clarke B.L., Khosla S. Physiology of bone loss. Radiol Clin North Am 2010, 48(3):483-495.
24. Paquette B. Enhancement of genomic instability by 17beta-estradiol in minisatellite sequences of X-ray-transformed mouse 10T1/2 cells. Carcinogenesis 1996, 17(6):1221-1225.
25. Wood C.E., Hester J.M., Cline J.M. Mammary gland development in early pubertal female macaques. Toxicol Pathol 2007, 35:793-803.
26. Land C.E., Tokunaga M., Koyama K., et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003, 160(6):707-717.
27. Sigurdson A.J., Bhatti P., Chang S., et al. Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologies. Breast Cancer Res Treat 2009, 118(1):177-184.
28. Cussenot O., Azzouzi A.R., Nicolaiew N., et al. Cancel-Tassin G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007, 25(24):3596-3602.
29. Faisal A. Causes of radiologists' deaths: a survey of 400 cases in the literature. Radiat Med 2003, 21(3):108-111.
30. Buja A., Lange J.H., Perissinotto E., et al. Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data. Toxicol Ind Health 2005, 21(10):273-282.
31. Gun R.T., Parsons J., Crouch P., et al. Mortality and cancer incidence of Australian participants in the British nuclear tests in Australia. Occup Environ Med 2008, 65(12):843-848.
32. Myles P, Evans S, Lophatananon A. Diagnostic radiation procedures and risk of prostate cancer. Br J Cancer 2008;3;98(11):1852-6.
33. Bartstra R.W., Bentvelzen P.A., Zoetelief J., et al. The effects of fractionated gamma irradiation on induction of mammary carcinoma in normal and estrogen-treated rats. Radiat Res 2000, 153:557-569.
34. Debeb B.G., Xu W., Woodward W.A. Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia 2009, 14(1):11-17.
35. Risbridger G., Wang H., Young P., et al. Evidence that epithelial and mesenchymal estrogen receptor-a mediates effects of estrogen on prostatic epithelium. Dev Biol 2001, 229:432-442.
36. Fujimura T., Takahashi S., Urano T., et al. Increased expression of estrogen-related receptor alpha (ERR alpha) is a negative prognostic predictor in human prostate cancer. Int J Cancer 2007, 120:2325-2330.
37. Hermann RM, Wolff HA, Jarry H, et al. In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol. Radiat Oncol 2008;14;3:19.
38. Hillman G.G., Wang Y., Kucuk O., et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004, 3(10):1271-1279.
39. Zaire R., Notter M., Reidel W., et al. Unexpected rates of chromosomal instabilities and alterations of hormone levels in Numibian Uranium miners. Radiat Res 1997, 147(5):579-584.
40. Wagner S.E., Burch J.B., Bottai M., et al. Groundwater uranium and cancer incidence in South Carolina. Cancer Causes Control 2011, 22(1):41-50.
41. Shah S., Small E. Emerging biological observations in prostate cancer. Expert Rev Anticancer Ther 2010, 10(19):89-101.
42. Kosti O., Xu X., Veenstra T.D., et al. Urinary estrogen metabolites and prostate cancer risk: a pilot study. Prostate 2011, 71(5):507-516.
43. Roth C., Schmidberger H., Schaper O., et al. Cranial irradiation of female rats causes dose-dependent and age-dependent activation or inhibition of pubertal development. Pediatr Res 2000, 47(5):586-591.
44. Silasi G., Diaz-Heijtz R., Besplug J., et al. Selective brain response to acute and chronic low-dose X-ray irradiation in males and females. Biochem Biophys Res Commun 2004, 325:122-1235.
45. Kruijver FP, Balesar R, Espila AM, et al. Estrogen-receptor-beta distribution in the human hypothalamus: similarities and differences with ER alpha distribution. J Comp Neurol 2003;10;466(2):251-77.
46. Matsuda K, Sakamoto H, Mori H, et al. Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci Lett 2008;15;441(1):94-9.
47. Canonaco M., Giusi G., Madeo A., et al. A sexually dimorphic distribution pattern of the novel estrogen receptor G-protein-coupled receptor 30 in some brain areas of the hamster. J Endocrinol 2008, 196(1):131-138.
48. Gonzales R.J., Ansar S., Duckles S.P., et al. Androgenic/estrogenic balance in the male rat cerebral circulation: metabolic enzymes and sex steroid receptors. J Cereb Blood Flow Metab 2007, 27(11):1841-1852.
49. Mangano J.J. Geographical variation in US thyroid cancer incidence and a cluster near nuclear reactors in New Jersey, New York, and Pennsylvania. Int J Health Serv 2009, 39(4):643-661.
50. Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure?. Hormones (Athens) 2010, 9(2):103-108.
51. Zhu Y.S., Yen P.M., Chin W.W., et al. Estrogen and thyroid hormone interaction on regulation of gene expression. PNAS 1996, 93(22):12587-12592.
52. Rajoria S., Suriano R., Shanmugam A., et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010, 20(1):33-41.
53. Richardson D.B. Exposure to ionizing radiation in adulthood and thyroid cancer incidence. Epidemiology 2009, 20(2):181-187.
54. Mahoney M.C., Lawvere S., Falkner K.L., et al. Thyroid cancer incidence trends in Belarus: examining the impact of Chernobyl. Int J Epidemiol 2004, 33(5):1025-1033.
55. Azizi F., Smyth P. Breastfeeding and maternal and infant iodine nutrition. Clin Endocrinol (Oxf) 2009, 70(5):803-809.
56. Richardson D., Sugiyama H., Nishi N., et al. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950-2000. Radiat Res 2009, 72(3):368-382.
57. Schnyder S., Du N.T., Le H.B., et al. Estrogen treatment induces MLL aberrations in human lymphoblastoid cells. Leuk Res 2009, 33(10):1400-1404.
58. Le H., Singh S., Shih S.J., et al. Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. Genes Chromosomes Cancer 2009, 48(9):806-815.
59. Bryant PE, Riches AC, Terry SY. Mechanisms of the formation of radiation-induced chromosomal aberrations. Mutat Res 2010;14:701(1):23-6.
60. Thielmann H.W., Popanda O., Staab H.J. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan. J Cancer Res Clin Oncol 1999, 125(3-4):193-208.
61. Azarova A.M., Lin R.K., Tsai Y.C., et al. Genistein induces topoisomerase II beta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia. Biochem Biophys Res 2010, 399:66-71.
62. Issa J.J., Baylin S.B., Belinsky S.A. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996, 56:3655-3662.
63. Shen R., Tao L., Xu Y., et al. Reversibility of aberrant global DNA and estrogen receptor-α gene methylation distinguishes colorectal precancer from cancer. Int J Clin Exp Pathol 2009, 2:21-33.
64. Zurita M., Lara P.C., del Moral R., et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 2010, 10:217-220.
65. Raiche J., Rodriguez-Juarez R., Pogribny I., et al. Sex- and tissue-specific expression of maintenance and de novo DNA methyltransferases upon low dose X-irradiation in mice. Biochem Biophys Res Commun 2004, 325(1):39-47.
66. Liu W., Konduri S.D., Bansal S., et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006, 281(15):9837-9840.
67. Liu W., Ip M.M., Podgorsak M.B., et al. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res Treat 2009, 115(1):43-50.
68. Sayeed A., Konduri S.D., Liu W., et al. Estrogen receptor A inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007, 67:7746-7755.
69. Tan H., Zhong Y., Pan Z. Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell. BMC Cancer 2009, 9(31):1-8.
70. Teng J., Wang Z.Y., Jarrard D.F., et al. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocr Relat Cancer 2008, 15:351-364.
71. Wibowo E., Schellhammer P., Wassersug R.J. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprovation therapy. J Urol 2011, 185(1):17-23.
72. Di Leva G., Gasparini P., Piovan C., et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010, 102(10):706-721.
73. Chai Y., Hei T.K. Radiation induced bystander effect in vivo. Acta Med Nagasaki 2008, 53:65-69.
74. Morgan W.F. Non target and delayed effects of exposure to ionizing radiation: II Radiation induced genomic instability and bystander effects in vivo, clastogenic factors and transgenerational effects. Radiat Res 2003, 159:581-596.
75. Koturbash I., Rugo R.E., Hendricks C.A., et al. Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo. Oncogene 2006, 25(31):4267-4275.
76. Agrawal A., Chandra D., Kale R.K. Radiation induced oxidative stress: II Studies in liver as a distant organ of tumor bearing mice. Mol Cell Biochem 2001, 22:9-17.
77. Kumar A., Klinge C.M., Goldstein R.E. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol 2010, 36(5):1067-1080.
78. Tsukimoto M., Homma T., Ohshima Y., et al. Involvement of purinergic signaling in cellular response to gamma radiation. Radiat Res 2010, 173(3):298-309.
79. Sugden P.H., Markou T., Fuller S.J., et al. Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1/2) are formed endogenously in intact cardiac myocytes and are enzymically active. Cell Signal 2011, 23(2):468-477.
80. Kim C.S., Kim J.M., Nam S.Y., et al. Low-dose of ionizing radiation enhances cell proliferation via transient ERK1/2 and p38 activation in normal human lung fibroblasts. J Radiat Res (Tokyo) 2007, 48(5):407-415.
81. Azria D., Larbouret C., Cunat S., et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 2005, 7(1):156-163.
82. Hofling M., Lofgren L., von Schoultz E., et al. Carlstrom K, Soderqvist G. Association between serum testosterone levels, cell proliferation and progesterone receptor content in normal ad malignant breast tissue in posmenopausal women. Gynecol Endocrinol 2008, 24(7):405-410.
83. Kiss R., de Launoit Y., Wouters W., et al. Inhibitory action of androstenedione on the proliferation and cell cycle kinetics of aroma. Eur J Cancer Clin Oncol 1989, 25:837-843.
84. Shao C., Folkard M., Held K.D. Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation. BMC Cancer 2008, 30(8):184-187.
85. Joubert A., Van Zyl H., Laurens J., et al. C2- and C4-position 17β-estradiol metabolites and their relation to breast cancer. Biocell 2009, 33(3):137-140.
86. Kanda R., Hayata I. Effects of estradiol on radiation-induced chromosome aberrations in human lymphocytes. J Radiat Res 1999, 40:95-100.
87. Zhang Y., Zhao H., Asztalos S., et al. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res 2009, 7(4):498-510.
88. Kovalchuk O., Tryndyak V.P., Montgomery B., et al. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007, 15:6. 16.